About The Study: The findings of this study provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate glucagon-like peptide 1 receptor agonists (GLP-1RAs) for alcohol use disorder.
Corresponding Author: To contact the corresponding author, Christian S. Hendershot, PhD, email christian.hendershot@usc.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2024.4789)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.4789?guestAccessKey=5def1990-2a00-4771-8c9e-e19711b10db9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021225
JAMA Psychiatry